Defence Therapeutics (TSE:DTC) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Defence Therapeutics Inc. announces corporate changes including the return of founder Sebastien Plouffe as CEO, board restructurings with two new members, and the initiation of financing strategies to advance its innovative oncology programs. These strategic moves highlight the company’s continued growth and development in the biopharmaceutical sector, aiming to enhance its pipeline of radiopharmaceuticals and immune-oncology vaccines.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.